Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated February 21, 2024, reports on interim results from the LATITUDE phase III clinical trial. The trial evaluates ViiV Healthcare's long-acting injectable HIV treatment, Cabenuva (cabotegravir + rilpivirine), specifically in individuals living with HIV who face challenges adhering to daily oral therapy.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a clinical trial update and does not contain financial statements or quantitative financial data.
Material Changes and Clinical Results
- Superior Efficacy: Interim data indicates Cabenuva demonstrated superior efficacy in maintaining viral load suppression compared to daily oral therapy in patients with adherence challenges.
- Study Modification: The Data Safety Monitoring Board (DSMB) recommended stopping randomization. Eligible participants receiving daily oral therapy are now being offered the option to transition to the long-acting injectable therapy.
- Study Scope: The LATITUDE study is ongoing across 31 sites in the U.S. and Puerto Rico, funded by the National Institute of Allergy and Infectious Diseases (NIAID) and conducted by the ACTG network.
Outlook, Management Commentary, and Risks
Kimberly Smith, MD, MPH, Head of R&D at ViiV Healthcare, described the outcome as "remarkable," emphasizing that optimizing therapy for those with adherence challenges is critical to ending the HIV epidemic. The full data set is expected to be presented at an upcoming scientific conference. GSK includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in their Annual Report on Form 20-F and Q4 2023 results.
Key Facts for Investor Verification
- Confirm the timeline for the presentation of the full LATITUDE data set at the upcoming scientific conference.
- Verify the commercial impact of the DSMB recommendation to transition patients to Cabenuva on ViiV Healthcare's revenue projections.
- Review the specific resistance criteria and safety data for the patient population with adherence challenges.
- Monitor regulatory filings for any updates to the prescribing information for Cabenuva based on these interim results.